Automatically diagnosing HER2 amplification status for breast cancer patients using large FISH images

Fluorescence in situ hybridization (FISH) is a technique that prepares acceptable results for molecular imaging biomarkers to precisely and dependably detect and diagnose disorders which are sign of cancers. Since contemporary manual FISH signal analysis is low-effective and inconsistent, it is an attractive research area to develop automated FISH image scanning systems and computer-aided diagnosis (CAD) schemes. The gene expression of epidermal growth factor receptors 2 (HER2) is highly related to results of patients with probable breast cancer. Although FISH technology outperforms other methods, yet it has so many drawbacks. Traditional approaches on FISH analysis are performed manually by clinician. This lets the results are highly dependent to human eye. Also FISH test colors constitutes of dark blue and black regions, it is reasonable that human eye will fail to distinguish between colors. Therefore, the success of computer vision algorithms compared to human eye in analyzing gene expression rate in FISH images will be discussed in this study. Another objective of this study is to expand a CAD program to evaluate HER2 status using acquired images that have MIRAX format. Different large FISH images were chosen for this study from pathology laboratory from Acibadem Maslak hospital. The proposed CAD scheme first applies pre-processing median and gaussian filters. An adaptive thresholding method followed by a watershed segmentation algorithm is employed to segment cells of interest areas. Furthermore, analyzable cells are found and non-detectable cells because of cell overlapping or image staining are discarded. The scheme then splits the detected analyzable region of interest into two red and green color spaces which is also followed by application of a scanning algorithm to detect the CEP17 green and HER2/neu red FISH signals separately. Finally, the proposed method calculates the ratio between independent green and red FISH signals of all analyzable cells identified on the image. The results express that the tool has the ability to automatically express HER2 status using very large FISH images. The results of the computer aided tool would lead to a more effective method in specifying HER2 state of probable patients.

[1]  John M S Bartlett,et al.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2014, Archives of pathology & laboratory medicine.

[2]  T. Lörch,et al.  Automated fluorescent in situ hybridization (FISH) analysis of t(9;22)(q34;q11) in interphase nuclei , 2006, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[3]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). , 2010, Archives of pathology & laboratory medicine.

[4]  Jean-Marc Guinebretière,et al.  SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases , 2013, BMC Cancer.

[5]  G Konecny,et al.  The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer. , 2000, Cancer treatment and research.

[6]  A D Carothers,et al.  Counting, measuring, and mapping in FISH-labelled cells: sample size considerations and implications for automation. , 1994, Cytometry.

[7]  K McPherson,et al.  ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. , 2000, BMJ.

[8]  Feng Jiang,et al.  Use of Interphase Fluorescence In Situ Hybridization as a Powerful Diagnostic Tool in Cytology , 2002, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[9]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Mitch Dowsett,et al.  HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity , 2014, Modern Pathology.

[11]  Ioannis Pitas,et al.  Automated evaluation of her-2/neu status in breast tissue from fluorescent in situ hybridization images , 2005, IEEE Transactions on Image Processing.

[12]  Bin Zheng,et al.  Automated Analysis of Fluorescent in situ Hybridization (FISH) Labeled Genetic Biomarkers in Assisting Cervical Cancer Diagnosis , 2010, Technology in cancer research & treatment.

[13]  M. Berger,et al.  Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.